Literature DB >> 21412179

Corticosteroids in the treatment of severe nocardia pneumonia in chronic granulomatous disease.

Alexandra F Freeman1, Beatriz E Marciano, Victoria L Anderson, Gulbu Uzel, Christ Costas, Steven M Holland.   

Abstract

Nocardia is 1 of the 5 main pathogens that infect chronic granulomatous disease patients. Despite aggressive antimicrobial therapy, medical treatment is not always successful and surgical resection of infected tissue has been intermittently required. We present 2 chronic granulomatous disease patients with severe Nocardia pneumonia whose pulmonary status worsened despite appropriate antimicrobials, but then improved clinically and radiographically with the addition of corticosteroids.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21412179      PMCID： PMC3151540          DOI： 10.1097/INF.0b013e318218181d

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  12 in total

Review 1.  The immune reconstitution inflammatory syndrome.

Authors:  Samuel A Shelburne; Richard J Hamill
Journal:  AIDS Rev       Date:  2003 Apr-Jun       Impact factor: 2.500

2.  Eosinophilic pneumonia as a presentation of occult chronic granulomatous disease.

Authors:  D Trawick; A Kotch; R Matthay; R J Homer
Journal:  Eur Respir J       Date:  1997-09       Impact factor: 16.671

Review 3.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

4.  Corticosteroid therapy for refractory infections in chronic granulomatous disease: case reports and review of the literature.

Authors:  Marco A Yamazaki-Nakashimada; E Richard Stiehm; Dino Pietropaolo-Cienfuegos; Victor Hernandez-Bautista; Francisco Espinosa-Rosales
Journal:  Ann Allergy Asthma Immunol       Date:  2006-08       Impact factor: 6.347

5.  Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease.

Authors:  D M Margolis; D A Melnick; D W Alling; J I Gallin
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

6.  Successful treatment with methylprednisolone pulse therapy for a life-threatening pulmonary insufficiency in a patient with chronic granulomatous disease following pulmonary invasive aspergillosis and Burkholderia cepacia infection.

Authors:  M Okano; M Yamada; M Ohtsu; N Kawamura; Y Sakiyama; K Aoi; S Gandoh; M Fujita; K Kobayashi
Journal:  Respiration       Date:  1999 Nov-Dec       Impact factor: 3.580

7.  Chronic granulomatous disease. Report on a national registry of 368 patients.

Authors:  J A Winkelstein; M C Marino; R B Johnston; J Boyle; J Curnutte; J I Gallin; H L Malech; S M Holland; H Ochs; P Quie; R H Buckley; C B Foster; S J Chanock; H Dickler
Journal:  Medicine (Baltimore)       Date:  2000-05       Impact factor: 1.889

8.  Fatal Aspergillus pneumonia in chronic granulomatous disease.

Authors:  J K Kelly; A R Pinto; W A Whitelaw; O P Rorstad; T J Bowen; D S Matheson
Journal:  Am J Clin Pathol       Date:  1986-08       Impact factor: 2.493

9.  Nocardia infection in chronic granulomatous disease.

Authors:  Susan E Dorman; Shireen V Guide; Patricia S Conville; Ellen S DeCarlo; Harry L Malech; John I Gallin; Frank G Witebsky; Steven M Holland
Journal:  Clin Infect Dis       Date:  2002-07-23       Impact factor: 9.079

10.  Steroid therapy for bronchopneumonia in chronic granulomatous disease.

Authors:  M Narita; M Shibata; T Togashi; K Tomizawa; S Matsumoto
Journal:  Acta Paediatr Jpn       Date:  1991-04
View more
  9 in total

1.  Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease.

Authors:  Aristóteles Álvarez-Cardona; Ana Luisa Rodríguez-Lozano; Lizbeth Blancas-Galicia; Francisco Eduardo Rivas-Larrauri; Marco A Yamazaki-Nakashimada
Journal:  J Clin Immunol       Date:  2011-11-26       Impact factor: 8.317

2.  Corticosteroid therapy for liver abscess in chronic granulomatous disease.

Authors:  Jennifer W Leiding; Alexandra F Freeman; Beatriz E Marciano; Victoria L Anderson; Gulbu Uzel; Harry L Malech; SukSee DeRavin; David Wilks; Aradhana M Venkatesan; Christa S Zerbe; Theo Heller; Steven M Holland
Journal:  Clin Infect Dis       Date:  2011-12-09       Impact factor: 9.079

3.  Psychrobacter immobilis septicemia in a boy with X-linked chronic granulomatous disease and fulminant hepatic failure.

Authors:  Panida Sriaroon; Araceli Elizalde; Elena E Perez; Jennifer W Leiding; Grace M Aldrovandi; John W Sleasman
Journal:  J Clin Immunol       Date:  2013-11-12       Impact factor: 8.317

4.  Nocardiosis Associated with Primary Immunodeficiencies (Nocar-DIP): an International Retrospective Study and Literature Review.

Authors:  Olivier Lortholary; Steven M Holland; Emmanuel Lafont; Beatriz E Marciano; Nizar Mahlaoui; Bénédicte Neven; Jacinta Bustamante; Veronica Rodriguez-Nava; Amit Rawat; Miren Josebe Unzaga; Alain Fischer; Stéphane Blanche; David Lebeaux
Journal:  J Clin Immunol       Date:  2020-09-12       Impact factor: 8.317

5.  Blood culture positive Nocardia asteroides infection: a case report.

Authors:  Wolfgang Höpler; Hermann Laferl; Marton Szell; Peter Pongratz; Irmgard Brandl; Gerhard Tucek; Christoph Wenisch
Journal:  Wien Med Wochenschr       Date:  2012-11-28

Review 6.  Disease Presentation, Treatment Options, and Outcomes for Myeloid Immunodeficiencies.

Authors:  Elizabeth M Kang
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

Review 7.  Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.

Authors:  Beatriz E Marciano; Steven M Holland
Journal:  Front Immunol       Date:  2017-08-09       Impact factor: 7.561

8.  Concomitant use of corticosteroid and antimicrobials for liver abscesses in patients with chronic granulomatous disease.

Authors:  Kyung-Sue Shin; Mu Suk Lee
Journal:  Korean J Pediatr       Date:  2016-04-30

Review 9.  A Review of Chronic Granulomatous Disease.

Authors:  Danielle E Arnold; Jennifer R Heimall
Journal:  Adv Ther       Date:  2017-11-22       Impact factor: 3.845
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.